Literature DB >> 24551297

EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix.

Qing Li1, Yongfeng Tang2, Xue Cheng2, Jie Ji2, Jingmin Zhang2, Xiaojun Zhou3.   

Abstract

The purpose of this study was to evaluate the protein expression and gene amplification of epithelial growth factor receptor (EGFR) in intraepithelial neoplasias and squamous cell carcinoma of the cervix and to determine the value of EGFR in carcinogenesis, progression, and prognosis of cervical cancer. EGFR protein expression and gene amplification involved gene copy number in 75 cases of cervical various lesions were evaluated using immunohistochemistry and by fluorescence in situ hybridization (FISH) techniques. Expression of EGFR was observed in 76.00% of the high-grade CIN and 79.17% of the invasive carcinomas. In contrast, there were low levels of EGFR expression in chronic cervicitis (1/10) and low-grade CIN (7/16). There were statistically significant differences among them (P<0.05). Gene amplification was detected in 20.51% high-grade CIN and invasive carcinoma, but there only 4.35% EGFR gene amplification was observed in chronic cervicitis and low grade CIN. Among the 42 patients with negative or low levels of EGFR expression, 26 patients (61.90%) were found to have diploidy and 11 patients (26.20%) to have balanced triploidy. However, among the 20 patients with an intermediate and high levels of EGFR protein expression, 13 (65.00%) were found to have balanced polyploidy or gene amplification. All cases of EGFR gene amplification involved intermediate and high levels of protein expression. EGFR may be involved in the carcinogenesis of the cervix and may be an early event during the carcinogenesis. Overexpression of EGFR protein may result from gene amplification and increases in gene copy number.

Entities:  

Keywords:  Cervix neoplasms; EGFR; FISH; gene amplification; gene copy number; protein expression

Mesh:

Substances:

Year:  2014        PMID: 24551297      PMCID: PMC3925921     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Fluorescence in situ hybridization in cervical smears: detection of numerical aberrations of chromosomes 7, 3, and X and relationship to HPV infection.

Authors:  C Mian; D Bancher; P Kohlberger; C Kainz; A Haitel; K Czerwenka; J Stani; G Breitenecker; H Wiener
Journal:  Gynecol Oncol       Date:  1999-10       Impact factor: 5.482

2.  Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.

Authors:  S Tangjitgamol; P T Ramirez; C C Sun; H T See; A Jhingran; J J Kavanagh; M T Deavers
Journal:  Int J Gynecol Cancer       Date:  2005 Jul-Aug       Impact factor: 3.437

Review 3.  Epidermal growth factor receptor as a biomarker for cervical cancer.

Authors:  T Soonthornthum; H Arias-Pulido; N Joste; L Lomo; C Muller; T Rutledge; C Verschraegen
Journal:  Ann Oncol       Date:  2011-02-16       Impact factor: 32.976

4.  [Immunohistochemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors].

Authors:  S Tomov; S Popovska; T Veselinova; G Gorchev; A Velkova
Journal:  Akush Ginekol (Sofiia)       Date:  2005

5.  A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.

Authors:  A Goncalves; M Fabbro; C Lhommé; L Gladieff; J-M Extra; A Floquet; L Chaigneau; A Tisseron Carrasco; P Viens
Journal:  Gynecol Oncol       Date:  2007-11-05       Impact factor: 5.482

6.  Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

Authors:  Adhemar Longatto-Filho; Céline Pinheiro; Olga Martinho; Marise A R Moreira; Luiz F J Ribeiro; Geraldo S Queiroz; Fernando C Schmitt; Fátima Baltazar; Rui M Reis
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

7.  Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression.

Authors:  R Marzano; G Corrado; R Merola; C Sbiroli; F Guadagni; E Vizza; F Del Nonno; M Carosi; M Galati M; I Sperduti; A M Cianciulli
Journal:  Eur J Cancer       Date:  2004-07       Impact factor: 9.162

Review 8.  Chemotherapy for recurrent cervical cancer.

Authors:  D Pectasides; K Kamposioras; G Papaxoinis; E Pectasides
Journal:  Cancer Treat Rev       Date:  2008-07-26       Impact factor: 12.111

9.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544

10.  The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer.

Authors:  Akin Atmaca; Dominique Werner; Claudia Pauligk; Kristina Steinmetz; Ralph Wirtz; Hans-Michael Altmannsberger; Elke Jäger; Salah-Eddin Al-Batran
Journal:  BMC Cancer       Date:  2012-11-15       Impact factor: 4.430

View more
  9 in total

1.  MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer.

Authors:  Zhenfeng Hao; Jishi Yang; Chenghai Wang; Yaoyao Li; Yu Zhang; Xiaoyun Dong; Liulin Zhou; Jing Liu; Yanqing Zhang; Jing Qian
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints.

Authors:  Erin A Blake; Malcolm S Ross; Megan E Ross; Koji Matsuo; Emily T Silverstein; Lilibeth R Torno; Rohit Bhargava; Miriam D Post; Diane M Da Silva; Sarah Taylor; Saloni Walia; Lynda Roman; Troy A McEachron
Journal:  Arch Gynecol Obstet       Date:  2021-08-15       Impact factor: 2.344

3.  Gene amplification of EGFR and its clinical significance in various cervical (lesions) lesions using cytology and FISH.

Authors:  Qing Li; Xue Cheng; Jie Ji; Jingmin Zhang; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.

Authors:  Qinghua Xu; Jinying Chen; Shujuan Ni; Cong Tan; Midie Xu; Lei Dong; Lin Yuan; Qifeng Wang; Xiang Du
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

5.  High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status.

Authors:  John P Veluchamy; A Marijne Heeren; Jan Spanholtz; Jaap D H van Eendenburg; Daniëlle A M Heideman; Gemma G Kenter; Henk M Verheul; Hans J van der Vliet; Ekaterina S Jordanova; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2016-10-25       Impact factor: 6.968

6.  MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.

Authors:  Adrian J Luna; Rosa T Sterk; Anastacia M Griego-Fisher; Joon-Yong Chung; Kiersten L Berggren; Virginie Bondu; Pamela Barraza-Flores; Andrew T Cowan; Gregory N Gan; Emrullah Yilmaz; Hanbyoul Cho; Jae-Hoon Kim; Stephen M Hewitt; Julie E Bauman; Michelle A Ozbun
Journal:  PLoS Pathog       Date:  2021-01-22       Impact factor: 6.823

7.  Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS-MAPK signaling pathway.

Authors:  A-Ram Kang; Hyoung-Tae An; Jesang Ko; Eui-Ju Choi; Seongman Kang
Journal:  Oncotarget       Date:  2017-10-10

8.  Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells.

Authors:  Xuanxuan Wang; Yanjun Gu; Hai Liu; Liming Shi; Xiaonan Sun
Journal:  Onco Targets Ther       Date:  2018-03-05       Impact factor: 4.147

9.  Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines.

Authors:  Arturo Valle-Mendiola; Ricardo Bustos-Rodríguez; Vanihamin Domínguez-Melendez; Octavio Zerecero-Carreón; Adriana Gutiérrez-Hoya; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  Oncol Lett       Date:  2022-01-05       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.